Administering monoclonal antibodies to respectively neutralize TNF-α and IGF1 produced by CX3CR1+ cells from Marfan Syndrome (MFS) patients greatly suppressed the cocultured MFS patient-specific induced pluripotent stem cell-derived vascular smooth muscle cell inflammation.
[Journal of Clinical Investigation]